Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why

Ribosome biogenesis and cancer: basic and translational challenges

(2018) Xosé R. Bustelo et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

(2017) Tracy Murphy et al.   EXPERT OPINION ON PHARMACOTHERAPY

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma

(2017) Isabel J.F. Hofman et al.   HAEMATOLOGICA

Management of Anaplastic Large Cell Lymphoma

(2017) Dai Chihara et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

TP53 mutation and survival in aggressive B cell lymphoma

(2017) Thorsten Zenz et al.   INTERNATIONAL JOURNAL OF CANCER

The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types

(2017) Laura Fancello et al.   Oncotarget

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma

(2017) Isabel J.F. Hofman et al.   HAEMATOLOGICA

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target

(2016) Michael T. Werner et al.   BLOOD

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients

(2016) Blanca Scheijen et al.   HAEMATOLOGICA

Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways

(2016) Dariusz Stępiński   HISTOCHEMISTRY AND CELL BIOLOGY

Role of ribosomal protein mutations in tumor development (Review)

(2016) KAVEH M. GOUDARZI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

(2016) I J F Hofman et al.   LEUKEMIA

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

(2016) A Stengel et al.   LEUKEMIA

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relationship between the nucleolus and cancer: Current evidence and emerging paradigms

(2016) Ines Orsolic et al.   SEMINARS IN CANCER BIOLOGY

The pre-existing population of 5S rRNA effects p53 stabilization during ribosome biogenesis inhibition

(2016) Carmine Onofrillo et al.   Oncotarget

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

(2016) Jaclyn Quin et al.   Oncotarget

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients

(2016) Blanca Scheijen et al.   HAEMATOLOGICA

The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy

(2015) Simone J. Woods et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

(2015) R. Guieze et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

(2015) V. Ljungstrom et al.   BLOOD

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations driving CLL and their evolution in progression and relapse

(2015) Dan A. Landau et al.   NATURE

Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia

(2015) Brunangelo Falini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Lymphoblastic Leukemia in Children

(2015) Stephen P. Hunger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate

(2015) F Scala et al.   ONCOGENE

Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

(2015) Elisa Brighenti et al.   Oncotarget

Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia

(2015) Lawrence WC Chan et al.   Scientific Reports

Targeting the nucleolus for cancer intervention

(2014) Jaclyn E. Quin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis

(2014) A. Stengel et al.   BLOOD

A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity

(2014) Karita Peltonen et al.   CANCER CELL

Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome

(2014) A. Alhejaily et al.   CLINICAL CANCER RESEARCH

p53 and ribosome biogenesis stress: The essentials

(2014) Lior Golomb et al.   FEBS LETTERS

Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency

(2014) Taina T. Nieminen et al.   GASTROENTEROLOGY

High Frequency ofRPL22Mutations in Microsatellite-Unstable Colorectal and Endometrial Tumors

(2014) Ana M. Ferreira et al.   HUMAN MUTATION

Selective Inhibition of rDNA Transcription by a Small-Molecule Peptide That Targets the Interface between RNA Polymerase I and Rrn3

(2014) Katrina Rothblum et al.   MOLECULAR CANCER RESEARCH

Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress

(2014) K. Peltonen et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis

(2013) Sladana Bursac et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Functional ribosome biogenesis is a prerequisite for p53 destabilization: impact of chemotherapy on nucleolar functions and RNA metabolism

(2013) Kaspar Burger et al.   BIOLOGICAL CHEMISTRY

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

(2013) Z. Y. Xu-Monette et al.   BLOOD

Targeting the nucleolus for cancer-specific activation of p53

(2013) Denis Drygin et al.   DRUG DISCOVERY TODAY

Targeting RNA polymerase I transcription and the nucleolus for cancer therapy

(2013) Ross D Hannan et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL

(2013) Gannie Tzoneva et al.   NATURE MEDICINE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network

(2013) Lilyn Daftuar et al.   PLoS One

5S Ribosomal RNA Is an Essential Component of a Nascent Ribosomal Precursor Complex that Regulates the Hdm2-p53 Checkpoint

(2013) Giulio Donati et al.   Cell Reports

The 5S RNP Couples p53 Homeostasis to Ribosome Biogenesis and Nucleolar Stress

(2013) Katherine E. Sloan et al.   Cell Reports

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B

(2012) S. Rao et al.   BLOOD

Management of indolent lymphoma: Where are we now and where are we going

(2012) Matthew A. Lunning et al.   BLOOD REVIEWS

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

(2012) A. K. Witkiewicz et al.   CLINICAL CANCER RESEARCH

Frequent mutations in the RPL22 gene and its clinical and functional implications

(2012) Akiva P. Novetsky et al.   GYNECOLOGIC ONCOLOGY

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

(2012) Kim De Keersmaecker et al.   NATURE GENETICS

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion

(2011) M. Mian et al.   ANNALS OF ONCOLOGY

The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia

(2011) P. Ouillette et al.   CLINICAL CANCER RESEARCH

CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients

(2011) I. Iacobucci et al.   CLINICAL CANCER RESEARCH

Selective inhibition of rRNA transcription downregulates E2F-1: a new p53-independent mechanism linking cell growth to cell proliferation

(2011) Giulio Donati et al.   JOURNAL OF CELL SCIENCE

The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells

(2011) G Donati et al.   ONCOGENE

Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases

(2011) E Colombo et al.   ONCOGENE

The RNA Polymerase I Transcription Machinery: An Emerging Target for the Treatment of Cancer

(2010) Denis Drygin et al.   Annual Review of Pharmacology and Toxicology

Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study

(2010) F. Jardin et al.   BLOOD

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

Wisely chosen paths - regulation of rRNA synthesis

(2010) Ingrid Grummt   FEBS Journal

Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia

(2010) R. Okamoto et al.   HAEMATOLOGICA

Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels

(2010) Kaspar Burger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

(2010) T Zenz et al.   LEUKEMIA

Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway

(2010) C Deisenroth et al.   ONCOGENE

Nucleolar protein B23 has molecular chaperone activities

(2010) Attila Szebeni et al.   PROTEIN SCIENCE

Chronic Myeloid Leukemia: A Historical Perspective

(2010) John M. Goldman   SEMINARS IN HEMATOLOGY

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy

(2009) D. Trere et al.   ANNALS OF ONCOLOGY

Driving ribosome assembly

(2009) Dieter Kressler et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner

(2009) Y.-X. Cui et al.   BLOOD

A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia

(2009) Daniel L. Van Dyke et al.   BRITISH JOURNAL OF HAEMATOLOGY

Signaling to p53: Ribosomal Proteins Find Their Way

(2009) Yanping Zhang et al.   CANCER CELL

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Growth control and ribosome biogenesis

(2009) Harri Lempiäinen et al.   CURRENT OPINION IN CELL BIOLOGY

The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein

(2009) Massimo Derenzini et al.   JOURNAL OF PATHOLOGY

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

(2009) H Seifert et al.   LEUKEMIA

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD

Loss of Retinoblastoma Tumor Suppressor Protein Makes Human Breast Cancer Cells More Sensitive to Antimetabolite Exposure

(2008) M. Derenzini et al.   CLINICAL CANCER RESEARCH

Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11

(2008) Xiao-Xin Sun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Why does cytotoxic chemotherapy cure only some cancers?

(2008) Philip Savage et al.   Nature clinical practice. Oncology